-
2024-517031-51-00
7
Heart Failure
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-514246-37-00
4
Idiopathic pulmonary fibrosis (IPF)
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-523425-17-00
4
Proteinuric kidney diseases
-
2025-524703-76-00
5
Urinary tract infection with systemic involvement (UTI: definite, prob
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2022-501551-90-00
10
2023-12-13
Prostate cancer
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-522936-14-00
6
2026-01-27
Pulmonary hypertension
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer